IMANasdaq

ImageneBio, Inc.

Healthcare·Immunology·San Diego, CA, United States
ImmunologyDermatology

ImageneBio, Inc. (IMA): 1 pipeline candidate · 1 upcoming catalyst · ~24 mo cash runway. Updated within the last hour.

6.3/10

BioSniper Score

5-factor signal · derived from public data

Cash Runway6.6

23.6 months

Financial Health9.7

D/E 0.11

Pipeline MaturityN/A

N/A

Pipeline Breadth3.3

1 candidate

Catalyst Momentum2.0

1 upcoming, next in ~196d

Insider Signal10.0

5 buys · 0 sells (180d)

A transparent, data-derived signal for ImageneBio, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$62.5M

Cash

$76.0M

Quarterly Burn

$14.8M

Runway

23.6 mo

Revenue

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Jun 2028
Today~26 mo out
Catalyst within runway

Pipeline (1 candidate)

DrugPhase
img-007

Upcoming Catalysts (1)

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

35

Total value held

$18.8M

HolderSharesValue
bvf inc/il1,110,002$5.6M
vanguard capital management llc650,310$3.3M
omega fund management, llc455,361$2.3M
orbimed advisors llc378,556$1.9M
rtw investments, lp334,445$1.7M
blackrock, inc.129,214$646K
citadel advisors llc124,345$622K
renaissance technologies llc81,696$408K
adage capital partners gp, l.l.c.66,666$333K
geode capital management, llc59,929$300K

Showing top 10 of 35 institutional holders of ImageneBio, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.

·CEO: Dr. Kristin Yarema Ph.D.

Frequently asked questions

How many drug candidates are in ImageneBio, Inc.'s pipeline?

ImageneBio, Inc. (IMA) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.

What is ImageneBio, Inc.'s next catalyst?

ImageneBio, Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: img-007" — expected December 31, 2026.

What is ImageneBio, Inc.'s cash runway?

Based on its most recent reported cash balance and quarterly burn rate, ImageneBio, Inc. has approximately 23.6 months of cash runway.

What is ImageneBio, Inc.'s market capitalization?

ImageneBio, Inc.'s market capitalization is approximately $62.5M.

Who is the CEO of ImageneBio, Inc.?

Dr. Kristin Yarema Ph.D. is the chief executive officer of ImageneBio, Inc. (IMA).

Get the full picture on ImageneBio, Inc.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.